Results 11 to 20 of about 19,854 (197)
Journal of Lipid Research, 2012 PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL receptor.
Gilles Lambert +4 more
doaj +4 more sources
The Multifaceted Biology of PCSK9 [PDF]
Endocrine Reviews, 2021 Abstract This article reviews the discovery of PCSK9, its structure–function characteristics, and its presently known and proposed novel biological functions. The major critical function of PCSK9 deduced from human and mouse studies, as well as cellular and structural analyses, is its role in increasing the levels of circulating low ...
Nabil G Seidah, Annik Prat
openaire +2 more sources
Swiss Medical Weekly, 2015 The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces LDL receptor recycling, leading to a decrease of low-density lipoprotein cholesterol (LDL-C) receptors on the surface of hepatocytes and a subsequent increase of circulating LDL-C levels.
Gencer, B +2 more
openaire +8 more sources
Frontiers in Physiology, 2023 Familial hypercholesterolemia (FH) is a globally underdiagnosed genetic condition associated with premature cardiovascular death. The genetic etiology data on Arab FH patients is scarce.
Noor Ahmad Shaik +18 more
doaj +1 more source
Past, Present, and Future of Familial Hypercholesterolemia Management
Methodist DeBakey Cardiovascular Journal, 2021 Familial hypercholesterolemia (FH) is a monogenic form of severe hypercholesterolemia that, if left untreated, is associated with early onset of atherosclerosis.
Viviane Z. Rocha, Raul D. Santos
doaj +1 more source
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
Медицинский совет, 2021 Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva +2 more
doaj +1 more source
Atherosclerosis Plus, 2021 Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels.
Maria Giovanna Lupo +11 more
doaj +1 more source
Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
Journal of Lipid Research, 2014 Secreted PCSK9 binds to cell surface LDL receptor (LDLR) and directs the receptor for lysosomal degradation. PCSK9 is potent at inducing LDLR degradation in cultured liver-derived cells, but it is considerably less active in immortalized fibroblasts.
My-Anh Nguyen +2 more
doaj +1 more source
Biomedicine & Pharmacotherapy, 2022 annually in Europe, 4 million people die from cardiovascular diseases, the main cause of which is atherosclerosis. In order to slow down the development of atherosclerotic plaques, the main therapeutic goal is to lower LDL cholesterol (LDL-C) level. Undoubtedly, statins are the basis of lipid-lowering therapy for many years.
Grzegorz, Grześk +6 more
openaire +2 more sources
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]
Journal of Lipid Research, 2015 Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact ...
Krista M. Schroeder +7 more
doaj +1 more source